title: Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints.
abstract: Oncolytic adenoviruses are modified to exploit the aberrant expression of proteins in cancer cells to obtain cancer-selective replication. Moreover, the natural tropism of oncolytic adenoviruses can be redirected to tumor cells. Clinical trials revealed that oncolytic viruses showed poor replication in the tumor that is due in part to the immune response against the virus. More recent data demonstrated that tumor infection might subvert the tumor immune system and lead to an anti-tumor immune response. In the next few years, combination of adenoviruses with immune checkpoint antibodies and other immune modulators will be tested in clinical trials.
authors: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: hjiang@mdanderson.org.
authors: Hong
authors: H
authors: Jiang
authors: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors: Candelaria
authors: C
authors: Gomez-Manzano
authors: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors: Yisel
authors: Y
authors: Rivera-Molina
authors: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors: Frederick F
authors: FF
authors: Lang
authors: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors: Charles A
authors: CA
authors: Conrad
authors: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jfueyo@mdanderson.org.
authors: Juan
authors: J
authors: Fueyo
mesh_terms: D000256:Adenoviridae / Q000502:physiology*; D000818:Animals; D059447:Cell Cycle Checkpoints; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000503:physiopathology* / Q000628:therapy*; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000502:physiology*